A Study of the Safety, Tolerability and Pharmacokinetics of ALN-TTR02 in Japanese Healthy Volunteers

NCT02053454 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

12

Enrollment

INDUSTRY

Sponsor class

Conditions

Transthyretin (TTR)-Mediated Amyloidosis

Interventions

DRUG: patisiran (ALN-TTR02)
DRUG: Sterile Normal Saline (0.9% NaCl)

Sponsor

Alnylam Pharmaceuticals